Stockreport

PepGen Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Corporate Highlights

PepGen Inc.  (PEPG) 
PDF – The Company today reported positive initial results from the ongoing FREEDOM-DM1 trial in patients with DM1; mean splicing correction of 12.3% and 29.1% in 5 and 10 mg [Read more]